We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Oric Pharmaceuticals has closed a Series D financing to support the continued development of a clinical-stage, selective and potent glucocorticoid receptor antagonist, ORIC-101.